# Case Report: Cadonilimab plus anlotinib with radiotherapy for lung adenocarcinoma with pancreatic metastasis in later-line therapy

## TL;DR

A patient with advanced lung cancer and pancreatic metastasis had 11 months of disease control using a combination of cadonilimab, anlotinib, and radiotherapy.

## Contribution

This case report presents a novel combination therapy showing potential for later-line treatment of advanced lung adenocarcinoma.

## Key findings

- The patient achieved 11 months of progression-free survival with the treatment combination.
- The therapy was well-tolerated with only minor side effects.
- The case suggests a possible new treatment option for patients with limited therapy options.

## Abstract

Patients with advanced lung adenocarcinoma lacking driver gene mutations face the clinical dilemma of limited treatment options and poor prognosis in later-line therapy. Although immune checkpoint inhibitors (ICIs) combined with anti-angiogenic agents offer a promising approach, the optimal treatment strategy remains to be explored. In this report, we present a case of advanced lung adenocarcinoma with pancreatic metastasis treated with cadonilimab plus anlotinib and radiotherapy to the pancreatic lesion, resulting in 11 months of progression-free survival (PFS) and only minor side effects. This outcome suggests the potential value of cadonilimab and anlotinib in later-line therapy for advanced lung adenocarcinoma and provides a possible new treatment option for such patients.